“Technology Research and Development Three Months Ended March 31, 2026 2025 $ Change % Change (unaudited) (in thousands, except percentages) Technology research and development $ 45,921 $ 33,391 $ 12,530 38 % The increase in Technology research and development…”10-Q · May 5, 2026 ↗
Tempus AI, Inc.
TEM
Market read
Tempus AI, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.
- TEM's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if TEM's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- TEM's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +83.4% year over year.
- Operating margin changed +79.8 percentage points in the latest annual period.
- Net margin changed +82.5 percentage points in the latest annual period.
- Diluted shares increased 45.4% in the latest annual period.
- Product pipeline and R&D has repeated adverse evidence across 4 filings.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 10, 2026
58.73Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Interest Expense Three Months Ended March 31, 2026 2025 $ Change % Change (unaudited) (in thousands, except percentages) Interest expense $ (14,341 ) $ (18,003 ) $ 3,662 -20 % 40 The decrease in Interest expense for the three months ended March 31, 2026, comp…”10-Q · May 5, 2026 ↗
“We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.”10-Q · May 5, 2026 ↗
“We expect that our selling, general and administrative expenses will continue to increase in absolute dollars after our IPO, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, acc…”10-Q · Nov 4, 2025 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for TEM. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for TEM. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind TEM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AZNAstraZeneca PLCcustomerFeb 24, 2026 ▾
“We issued a warrant to our customer AstraZeneca in conjunction with the signing of the MSA in November 2021.”
AZNAstraZeneca PLCpartnerMay 5, 2026 ▾
“For a reconciliation of adjusted EBITDA to net loss, the most directly comparable financial measure stated in accordance with generally accepted accounting principles in the United States of America, or GAAP, and for additional information about adjusted EBIT…”
Depended on by
PSNLPersonalis, Inc.partnerMay 7, 2026 ▾
“We also have a collaboration with Tempus that enables Tempus to market our NeXT Personal ® Dx test to physicians for breast cancer, lung cancer, colorectal cancer and immuno-oncology monitoring, and to market and sell NeXT Personal to Tempus' pharmaceutical a…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 25 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TEM is currently a Follower in the organic co-movement group High-Beta Growth. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.